Total
0
Shares
Actinogen Medical (ASX:ACW) - Chairman Geoff Brooke (middle) & CEO Bill Ketelbey (right) - The Market Herald
Chairman Geoff Brooke (middle) & CEO Bill Ketelbey (right)
Source: Actinogen Medical
  • Actinogen Medical (ACW) is set to expand its intellectual property portfolio with two new patents
  • The healthcare stock filed the applications for its lead drug candidate, an Alzheimer's treatment known as Xanamen
  • Positively, the new submissions could extend the drug's patent life protection up to 2040
  • ACW's first patent covers a process which seeks to improve cognitive function or treat cognitive decline in healthy adults
  • Meanwhile, the second patent will protect Actinogen's scale-up manufacturing process
  • Looking ahead, Actinogen says it will continue to grow its patent portfolio and pursue opportunities to further advance its Xanamen treatment
  • Actinogen closed steady following today's news, with shares worth 2.2 cents each

Actinogen Medical (ACW) is set to expand its intellectual property portfolio with two new patents.

The healthcare stock filed the applications for its lead drug candidate, an Alzheimer's treatment known as Xanamen. Positively, the new submissions could extend the drug's patent life protection up to 2040.

ACW's first patent covers a process which seeks to improve cognitive function or treat cognitive decline in healthy adults. The company opted to pursue a patent based on a phase one clinical trial, which indicated Xanamen could improve cognitive function compared to a placebo in elderly patients.

The second patent will protect Actinogen's scale-up manufacturing process. It comes after the company worked with chemists and a Swiss-based contract development and manufacturing organisation (CDMO).

“Strengthening our IP portfolio and extending the patent life of protection over Xanamem is aligned with our broader commercialisation strategy," Actinogen CEO and Managing Director Dr Bill Ketelbey said.

"The potential to treat cognitively healthy subjects ... as well as treat those at risk of cognitive impairment, is a significant medical and commercial opportunity," he continued.

"Actinogen remains focused on maintaining and extending the protection of Xanamem to maximise its commercial potential," the CEO concluded.

Looking ahead, Actinogen says it will continue to grow its patent portfolio and pursue opportunities to further advance its Xanamen treatment.

Actinogen closed steady following today's news, with shares worth 2.2 cents each.


Subscribe


ACW by the numbers
More From The Market Herald
Azure Healthcare’s (ASX:AZV) subsidiary wins $1.6M contract

" Azure Healthcare’s (ASX:AZV) subsidiary wins $1.6M contract

Azure Healthcare’s (AZV) subsidiary, Austco Canada, has received $1.6 million contract to supply its Tacera Nurse Call platform to a new 350 be…
Recce Pharmaceuticals (ASX:RCE) - CEO, James Graham - The Market Herald

" Recce Pharmaceuticals’ (ASX:RCE) anti-infectives receive Japanese patent

Recce Pharmaceuticals (RCE) has received a Japanese patent for its synthetic anti-infectives Recce 327 (R327) and Recce 529 (R529).
Incannex Healthcare (ASX:IHL) - Chief Medical Officer, Dr Sud Agarwal (centre) - The Market Herald

" Incannex Healthcare (ASX:IHL) looks to fast-track treatment registration

Animal studies testing Incannex Healthcare’s (IHL) IHL-675A combination therapy have shown a response even better than predicted.
Imagion Biosystems (ASX:IBX) - Executive Chairman, Bob Proulx - The Market Herald

" Imagion Biosystems (ASX:IBX) completes $6M placement

Imagion Biosystems (IBX) has successfully completed a placement and raised $6 million.